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Epithelial ovarian cancer is responsible for 5.8% of cancer deaths.
The mortality rate increases with age and two-thirds of the deaths
occur after the age of 65. Seventy-five percent of these tumours
are at an advanced stage (III or IV) at the time of diagnosis. The
overall 5-year survival is about 30%. 
This SOR covers only the initial management of epithelial
ovarian cancer. It does not consider the management of recurrent
disease. Similarly it does not discuss tumours of low malignant
potential (borderline tumours), germ cell tumours or the manage-
ment of women with a genetic predisposition to ovarian adeno-
carcinoma. 
The SOR document for the management of epithelial ovarian
cancer was originally published in March 1998. The recommenda-
tions were reviewed and updated by the ovarian working group in
April 1999. The next update is planned for 2001. 
SCREENING 
For pre- or postmenopausal women without a family history of
ovarian cancer, routine population or individual screening
programmes by ultrasound and/or CA125 assay is not indicated
(standard). There is no risk-factor sufficiently powerful to identify
a population large enough for screening to have any benefit in
public health terms. Patients with a family history of ovarian
cancer can be offered a genetic cancer consultation (option). In
women with a genetically defined risk of ovarian cancer, or in
familial forms of ovarian cancer, screening is not recommended
outside a formal trial. In women with a definite genetic predisposi-
tion to cancer of the ovary, or in familial forms, it is recommended
to set up targeted screening programmes, but only within a
properly evaluated programme. 
DIAGNOSIS 
A pelvic mass detected clinically or an ovarian mass seen on ultra-
sound raises the possibility of ovarian cancer. An ovarian cancer
has certain characteristic features on suprapubic and transvaginal
pelvic ultrasonography (level of evidence B), but the definitive
diagnosis of malignancy can only be made histologically. 
The ultrasound report must be complete and unambiguous. It
must document: 
l the technique used 
l the phase of the menstrual cycle in premenopausal women 
l the size and topography of the lesion(s) 
l whether it is uni- or bilateral 
l whether it is entirely fluid filled, mixed, predominantly fluid
or predominantly solid 
l whether any solid component is homogeneous or heterogeneous. 
In the case of a cystic or predominantly cystic lesion, the report
must describe the thickness of the walls, the presence of septae
(single or multiple), the presence of papillae or endocystic or
exocystic vegetations and whether there are any associated signs
(e.g. fluid in the pouch of Douglas, ascites, lymphadenopathy,
hydronephrosis). 
Transvaginal colour doppler ultrasonography is not indicated at
diagnosis outside a controlled study. Its reliability in differenti-
ating benign from malignant ovarian tumours has yet to be proven
(level of evidence B). No other methods of imaging are indicated
routinely during initial evaluation. In the case of diagnostic diffi-
culty, ultrasonography may be complimented by CT scanning or
MRI (options). MRI gives the best anatomical detail when evalu-
ating large masses of uncertain origin (uterus or ovary). Similarly,
MRI may be of use in trying to distinguish tumour from certain
benign lesions (e.g. endometriosis, or some mature teratomas).
The information gained may help decide what kind of surgery
should be undertaken (i.e. laparoscopy or laparotomy) and
whether this should be carried out electively in a cancer centre. 
Evaluation of cysts – fine-needle aspiration for
cytology 
Fine-needle aspiration by the transabdominal or transvaginal route
for the cytological examination of all ovarian masses (solid or
mixed) is contra-indicated (standard). The management of purely
fluid cysts is different in premenopausal and post-menopausal
women. 
i) Post-menopausal women. Transvaginal aspiration of a purely fluid,
echogenic, thin-walled cyst of more than 5 cm diameter without
endocystic vegetations is contra-indicated (standard). These must be
followed, either by ultrasonography, or excised by a gynaecological
surgeon (standard). There is no consensus as to the management of
clear cysts of less than 5 cm in post-menopausal women. 
ii) Pre-menopausal women. There is no consensus as to the ideal
management. Fine-needle aspiration of purely fluid cysts with
echogenic contents and without endocystic vegetations is highly
controversial. If there is a high probability of the cyst being benign
and functional many gynaecologists will choose to aspirate the
cyst via the transvaginal route under ultrasound control. There are
reservations about this practice because of the difficulty in
interpreting diagnostic ultrasound in all patients, the results being
operator-dependent. The risk of a non-informative cytological
examination following aspiration is in the order of 25% and the
risk of recurrence is about 20%. 
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Preoperative imaging is not sufficient for precise staging. Except
for cases presenting with stage IV disease (e.g. with a pleural
effusion or supraclavicular nodes), surgical exploration and
histopathological examination are necessary for confirmation of
the histological diagnosis and for definitive staging (standard,
level of evidence B). CT scanning is not a useful preoperative
staging tool (standard, level of evidence B). MRI is only useful in
certain cases, for example, when surgical management will be
altered if there is involvement of the rectosigmoid, bladder or
pelvic wall (level of evidence B). 
POSTOPERATIVE IMAGING 
If all macroscopic disease has been removed at initial surgery, a
postoperative CT scan should not be done routinely. In the case of
extensive complete surgery resulting in major anatomical disrup-
tion, a postoperative abdomino-pelvic CT scan can facilitate
subsequent on-treatment evaluation (option). If initial surgery has
been incomplete, a baseline CT scan should be taken 3 weeks to 1
month after surgery, or immediately before the start of
chemotherapy, in order to follow subsequent response to treat-
ment. Similarly, a baseline abdomino-pelvic CT scan is necessary
if initial surgery is contra-indicated (e.g. if the patient is of poor
performance status) and when chemotherapy is to be given as
primary treatment (level of evidence B). 
TUMOUR MARKERS 
A serum CA125 assay before surgery and before the start of
chemotherapy is standard. Other markers (ACE, CA19.9) should
only be measured if the serum CA125 is not elevated at diagnosis,
notably in the case of mucinous or endometrioid tumours. In
young women, measurement of alpha-foetoprotein and beta-HCG
is recommended to exclude a germ cell tumour. 
The measurement of CA125 levels during chemotherapy is stan-
dard. An assay before each of six courses and a month after the last
course is recommended. 
EXTRAOVARIAN PERITONEAL CARCINOMA 
Malignant ovarian cancers presenting as peritoneal carcinomatosis
must be treated surgically without delay in a specialist cancer
setting (standard, level of evidence B). Assessment includes an
abdomino-pelvic ultrasound and the aspiration of ascitic fluid for
cytological analysis (standard), which may be followed by a CT
scan of the abdomen and pelvis (option). If an ovarian origin is
likely, there is no point in carrying out further investigations.
These are only appropriate if an alternative origin is suspected. For
patients whose performance status is too poor for surgery and who
would benefit from primary chemotherapy, a CT scan of the
abdomen and pelvis is undertaken as a base-line for follow-up on
treatment. 
HISTOLOGICAL DIAGNOSIS 
Good quality, adequately sized representative samples from the
ovarian tumour(s) must be examined (standard). Peritoneal
biopsies are not sufficient; they do not provide proof of ovarian
origin, nor the degree of malignancy (standard). 
A meticulous macroscopic examination taking into account the
clinical details must precede histological analysis. A medical
summary should accompany the surgically excised tissue samples.
The excised tissue, intact and unopened, must be transported as
rapidly as possible to the laboratory (standard). The choice of fixa-
tive is very important and must be appropriate for all analytical
tests that might be used (standard). 
The analysis should include: 
l the weight and measurement of all samples 
l a detailed macroscopic description of all excised pieces 
l multiple well directed samples from all ovarian lesion(s) (one
per centimetre along the greatest diameter), any extra-ovarian
spread and routine biopsies taken as part of surgical staging
(standard). 
The routine freezing of representative samples is recommended.
The intraoperative examination (frozen section) of ovarian
lesion(s) can guide surgery. Interpretation may be difficult for
epithelial tumours of the ovary and requires a good knowledge of
the clinical details and close collaboration with the surgical team.
The main limitation of a frozen section is the distinction between
very well differentiated adenocarcinomas and borderline tumours. 
Immuno-markers can be used to classify a poorly differentiated
tumour as an epithelial tumour, but unfortunately, none of the
commercially available immuno-marker kits are specific for these
tumour types. 
PATHOLOGICAL REPORTING 
Macroscopic features must be described precisely and include all
the samples received. Similarly, the histological description must
be precise and provide all the information necessary to make a
diagnosis of malignancy. It must also contain all factors necessary
for staging and prognosis: histological type, degree of differentia-
tion and description of any extra-ovarian spread. The conclusion
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MALIGNANT OVARIAN TUMOUR
SUSPECTED BY IMAGING
Standard
median laparotomy and abdominal
exploration with sample of ascites or
lavage for peritoneal cytology
Tumour limited to the ovaries?
Yes no
Disease limited
to the ovaries
Disease with extension
beyond the ovaries
Standard
total hysterectomy and bilateral salpingo-
oophorectomy
+ infragastric omentectomy
+ appendicectomy
+ maximum tumour reduction
Options
· bowel resection (rectosigmoid)
· pelvic and para-aortic lymphadenectomy
Recommendations
· avoid permanent colostomy
· pelvic and para-aortic lymph-
   adenectomy + bowel resection if tumour 
   resection is complete
Standard
Stages IA, IB:
• total hysterectomy and bilateral salpingo-
oophorectomy  and
• staging
- peritoneal cytology
- exploration of entire abdominal cavity
- appendicectomy
- nodal exploration (pelvic and para-aortic)
- routine peritoneal biopsies
Options
Stages 1A, 1B, grades 1-2, non-clear cell
disease in young women wishing to 
preserve fertility
· unilateral salpingo-oophorectomy + biopsy of
   contralateral ovary (1A) or bilateral salpingo-
   oophorectomy (1B),
· staging (see standard procedure)
· hysteroscopy and curettage
Figure 1 Surgery for ovarian cancer 20 P Kerbrat et al
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of the report must be clear and summarize both the macroscopic
and the histological findings. It must specify the side, the presence
or absence of exophytic vegetations and/or of a ruptured capsule,
the histological type, degree of differentiation and whether there is
any extension to pelvic or abdominal organs or to lymph nodes. In
cases of extensive surgery, it must also describe the quality of the
excision margins. Finally, it must include the results of the cyto-
logical examination of ascitic fluid or peritoneal lavage. 
CLASSIFICATION 
The standard classification of ovarian tumours is that of the
International Federation of Gynaecologists and Obstetricians
(FIGO) (standard). It is a pathological classification determined
after initial surgery. 
PROGNOSTIC FACTORS 
The independent prognostic factors that determine treatment
modalities are tumour extension (FIGO stage), the volume of
residual disease after initial surgery, the histological type, the
degree of differentiation (especially for the early stage disease),
age and performance status. 
THERAPEUTIC STRATEGY 
Surgery for cancer of the ovary 
Surgery for ovarian cancer should only be carried out by those
with extensive experience in oncology, gynaecology, general
surgery and endoscopic surgery. It should only be undertaken by
teams able to offer a multidisciplinary approach for the manage-
ment of these patients. 
Surgery for early stage disease (Figure 1) has two main aims:
adequate staging and the conservation of fertility (if this is possible
and the patient’s wish). Surgery for advanced disease is based on
the general principle of maximum tumour reduction with the
awareness that ultraradical surgery is a controversial issue.
Surgery for re-evaluation (second-look surgery) has a role in
clinical trials. 
The operative report must include a precise and detailed
description of the operative findings and of the surgery under-
taken. If a patient presents to a specialist centre following surgery
that is considered to be inadequate, a further staging operation
should be undertaken. Similarly, staging surgery should be under-
taken as soon as possible if a diagnosis of ovarian adenocarcinoma
has been made following minor surgery (e.g. laparoscopy). A re-
staging operation after laparoscopy must include the resection of
trochar tracks. 
Surgical treatment of early stage disease limited to the
ovaries (stages IA, IB) 
The standard surgical treatment for tumour limited to the ovaries
in post-menopausal women and women not wanting children is
total hysterectomy and bilateral salpingo-oophorectomy (TAH,
BSO) by para-median incision. Complete staging consists of
collection of ascitic fluid or peritoneal lavage for cytology, explo-
ration of the entire abdominal cavity, infracolic omentectomy and
appendicectomy, assessment of pelvic and para-aortic nodes and
routine peritoneal biopsies. There is no consensus as to the best
means of assessing retroperitoneal nodes. The therapeutic value of
lymphadenectomy has not been demonstrated, but it may be the
only way of excluding nodal metastases in early stage disease and
confirming stage I disease. 
In women with stages IA, IB, grades 1 or 2, non-clear cell
disease wishing to maintain their fertility, conservative surgery is
possible (option). If the tumour is unilateral, surgery consists of
the complete staging procedure plus unilateral oophorectomy and
examination of the contralateral ovary. Bilateral oophorectomy is
mandatory for bilateral tumours. An assessment of the uterine
cavity by hysteroscopy and curettage is mandatory in all cases.
Total hysterectomy with bilateral oophorectomy along with the
full staging procedure is recommended in women in whom fertility
is no longer desired. 
Surgical treatment of disease with extraovarian spread
(stages IC, II, III, IV) 
Standard treatment for patients presenting with advanced stage
disease consists of BSO by para-median incision with complete
excision of the lumbar-ovarian vessels, a total hysterectomy with
vaginal closure, a complete infragastric omentectomy and an
appendicectomy. The volume of tumour left in place after initial
surgery is of prognostic value. Patients without residual disease
(complete excision) or minimal residue (optimal excision) have a
better chance of a prolonged survival. Patients who have signifi-
cant residual tumour (sub-optimal excision) or who have only had
a biopsy, have a very poor prognosis. 
If the operation has resulted in complete or optimal tumour
resection, pelvic and para-aortic lymphadenectomy can be justi-
fied on several grounds: some experts consider this to be a thera-
peutic measure, metastatic nodes are markers of distant
metastases, and involved nodes can persist after chemotherapy. 
If a standard operation does not result in a complete or optimal
resection, additional interventions can be undertaken, including
excision of the entire genital tract, bowel resection and excision of
peritoneal metastases. Pelvic and para-aortic lymphadenectomy
can be undertaken if the abdominal tumour resection has been
complete or optimal and there is nodal enlargement. 
If a standard operation does not result in a complete or optimal
resection, chemotherapy can be started immediately and two or
three courses given before a second attempt at interval debulking
surgery (option). If the standard operation is likely to be difficult
(e.g. if the patient is in poor general health or has a fixed pelvis and
in some cases of stage IV disease), a limited exploration (by
laparotomy or laparoscopy) can be undertaken for precise staging
and for ovarian biopsies. The patient may then proceed rapidly to
two or three courses of chemotherapy before interval debulking
surgery is attempted (option). 
If a patient is referred to a specialist centre after a sub-optimal
resection, either a further operation can be undertaken immedi-
ately in an attempt to complete tumour resection (option), or two
or three courses of chemotherapy can be given before interval
debulking surgery (option). 
Tumour resection must be as complete as possible. Ultra-radical
surgery must only be considered if a prolonged postoperative
course would not delay the start of chemotherapy. 
The preoperative bowel preparation should be identical to that
used for bowel surgery. If a recto-sigmoid resection is necessary, a
low colorectal anastomosis should be fashioned if at all possible.
A reversible colostomy is a possible option. A permanent colostomy
will have a deleterious effect on patient quality of life. The opera-
tion report must include a detailed description of all lesions priorOvarian cancer 21
British Journal of Cancer (2001) 84 (Supplement 2), 18–23 © 2001 FNCLCC
to excision, a precise description of the surgery undertaken and a
precise description of the size and the localization of residual
tumour left in place. 
Surgery for re-evaluation and secondary tumour debulking 
Surgery for re-evaluation or ‘second look’ surgery is practiced
after initial standard surgery and first-line chemotherapy in a
patient in complete remission as judged clinically, by imaging and
by tumour markers. It is not recommended routinely as it has not
been shown to benefit patients (standard, level of evidence C). It
can be considered if it is likely to change subsequent therapy
(option) or as part of a therapeutic trial. It can be done by laparo-
tomy or by laparoscopy (option) if the operator is trained in the
technique. 
Surgical management if initial surgery has not been done
according to standard procedures 
This applies particularly if lymphadenectomy has been omitted. A
second operation can be undertaken, as studies have shown that
metastatic nodes can persist despite chemotherapy. Secondary
cytoreduction surgery for recurrence, or after completion of first-
line treatment, is controversial and has no proven benefit (level of
evidence C). It should only be considered if there are favourable
features such as a single mass or several masses which are likely to
be completely excised and in cases of late relapse. It should not be
considered in patients progressing on chemotherapy or in those
with disseminated peritoneal disease. 
Adjuvant treatment 
Adjuvant treatment for stage I and IIA disease (following
optimal staging and with histological grading) 
There is no indication for adjuvant treatment for stage IA GI
disease (standard) (Figure 2). There is no standard for stage IA,
G2–3 or clear cell tumours, IB, IC or IIA disease. The options are:
no additional treatment, chemotherapy based on platinum and
external beam abdomino-pelvic irradiation. 
For stage I disease, there is insufficient evidence to show that
adjuvant treatment (chemotherapy or abdomino-pelvic external
radiotherapy) improves overall survival (level of evidence C) but
there is a benefit from cisplatin-based chemotherapy in terms of
survival without recurrence, as compared to follow-up alone (level
of evidence C). 
For stage IA G2–3 or clear cell tumours, IB, IC and IIA disease,
external abdomino-pelvic radiotherapy, chemotherapy or no
additional treatment are options (level of evidence C). Additional
treatment is recommended for stage IC, IIA disease and for all
stages with G3 or clear cell tumours. 
The available data is not sufficient to differentiate the efficacy
of chemotherapy and external radiotherapy (level of evidence C),
but the chemotherapy regimens used in the comparative trials were
sub-optimal as compared to the chemotherapy currently used for
advanced disease. Toxicity is more severe (with a higher treatment
‘drop-out’ rate) with external radiotherapy as compared to
chemotherapy (level of evidence C). 
External irradiation should include the entire abdomino-pelvic
cavity (abdomino-pelvic irradiation) (standard). Irradiation of the
pelvis alone is not recommended (standard, level of evidence B).
Abdomino-pelvic irradiation requires the use of a linear acceler-
ator, with an open field technique using two antero-posterior or
four orthogonal beams with kidney shields at 15 Gy and liver
shields at 20 Gy. The exact status of the abdominal and pelvic
cavities must be taken into account before undertaking abdomino-
pelvic radiotherapy; there must be no macroscopic residual
disease. Toxicity is increased in patients who have undergone
multiple previous operations and in those receiving pelvic boosts
(level of evidence C). 
Intraperitoneal brachytherapy is not recommended (level of
evidence B). 
Patients should be considered for entry into therapeutic trials. 
Adjuvant treatment for stage IIB, IIC and III disease (without
residual disease and following optimal staging) 
There is no standard for stage IIB, IIC and III tumours without
disease (Figure 3). The options are platinum-based chemotherapy
and external abdomino-pelvic radiotherapy. 
For stage IIB, IIC and III tumours without residual disease,
adjuvant treatment is recommended. The available data is not
sufficient to differentiate the relative efficacy of chemotherapy and
external radiotherapy (level of evidence C), but the chemotherapy
used in comparative trials has been sub-optimal as compared to
current regimens. The nature of the toxicity of the two treatments
is different (level of evidence B). 
External radiotherapy must include the entire abdomino-pelvic
cavity (abdomino-pelvic radiotherapy) (standard). Toxicity is
increased following repeated surgery and with pelvic boosting
(level of evidence C). 
Intra-peritoneal brachytherapy is not recommended (level of
evidence B). 
Patients should be included in therapeutic trials. 
Additional treatment in advanced disease (IIB, IIC, III with
residual disease and IV) 
The standard treatment for advanced disease is combination
chemotherapy with an intravenous platin (Figure 4) at a dose-
intensity of 25 mg m–2 week–1 of cisplatin (75 mg m–2 over 3
weeks) or the equivalent dose of carboplatin, for at least six
courses (level of evidence C). 
EPITHELIAL OVARIAN CANCER
STAGES IA, B, C, IIA
Stage?
Grade?
Stages IA G1 Stages IA G2–3 or clear cell tumours,
IB, IC, IIA
Standard
no adjuvant treatment
Follow-up Follow-up
Standard
there is no standard
Options
· no adjuvant treatment
· platin-based chemotherapy
· abdomino-pelvic external beam radiotherapy
Recommendations
· adjuvant treatment for  stages IC and IIA
· inclusion in therapeutic trials
Figure 2 Adjuvant treatment of stages IA, IB, IC, IIA epithelial ovarian
cancer 22 P Kerbrat et al
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The options are: 
l an intravenous platin combined with intravenous paclitaxel 
l an intravenous platin combined with intravenous cyclo-
phosphamide and/or doxorubicin 
l intraperitoneal cisplatin combined with intravenous cyclo-
phosphamide. 
Intravenous carboplatin has equivalent efficacy to cisplatin (level
of evidence A) when given at an equivalent dose of 4:1. The non-
haematological toxicity of carboplatin is less than that of cisplatin,
but the haematological toxicity is greater (level of evidence B).
The optimal number of cycles of chemotherapy is unknown. The
available data does not support a benefit in terms of overall
survival in giving more than six courses (level of evidence C). 
There is a significant survival benefit with the addition of
doxorubicin to the cyclophosphamide, cisplatin combination (level
of evidence A). This benefit is seen even at doses that are sub-
optimal compared to current standards. It is not clear if the benefit
is a result of an increase in overall dose intensity or the addition of
doxorubicin per se. The additional toxicity related to the doxo-
rubicin was not evaluated in the meta-analysis. 
In stage III disease with residual disease post-surgery of ³ 1c m
and for stage IV, the combination of cisplatin-paclitaxel leads to an
increase in overall survival compared to the cisplatin-cyclophos-
phamide combination (level of evidence B). This is also true for
residual disease ≤ 1 cm (level of evidence B). When paclitaxel has
not been used as first-line chemotherapy, it is recommended that it
be used for recurrent disease. 
In the only study in which intraperitoneal cisplatin has been
combined with intravenous cyclophosphamide and compared to
intravenous cisplatin in stage III disease, an increase in overall
survival was seen in the intraperitoneal treatment arm for cases
with residual disease post initial surgery of < 2 cms (level of
evidence B). 
External beam abdomino-pelvic radiotherapy and intra-
peritoneal brachytherapy have no place in first-line treatment of
advanced disease where there is residual disease after surgery. 
The use of immunotherapy or hormone therapy is not recom-
mended as first line treatment in advanced disease (level of
evidence C). 
Consolidation treatment 
There is no standard treatment after second-look surgery (Figure 5).
In the absence of macroscopic disease, there is no difference in
overall survival between chemotherapy and external abdomino-
pelvic irradiation when used as consolidation treatment (level of
evidence C). The toxicity and toxicity-related ‘drop out’ rates are
higher for external radiotherapy compared to chemotherapy (level
of evidence C). 
There is little evidence to support any of the following options:
no treatment, more chemotherapy of the same type, intraperitoneal
chemotherapy, abdomino-pelvic irradiation or high-dose
chemotherapy. This is irrespective of whether there has been a
complete clinical or histological response, minimal macroscopic
or microscopic residual disease. 
EPITHELIAL OVARIAN CANCERS
STAGES IIB, C, III
WITHOUT RESIDUAL DISEASE AFTER SURGERY
Standard
there is no standard
Options
·  platin-based chemotherapy
·  abdomino-pelvic external beam radiotherapy
Evaluation after
adjuvant treatment
Figure 3 Adjuvant treatment of stages IIB, IIC, III epithelial ovarian cancer,
without residual disease after surgery 
EPITHELIAL OVARIAN CANCER
STAGES IIB, C, III WITH RESIDUAL DISEASE AFTER SURGERY
STAGE IV
Standard
platin-based intravenous polychemotherapy
Options
· platin and paclitaxel (intravenous)
· platin and cyclophosphamide and/or doxorubicin (intravenous)
· cisplatin (intraperitoneal) combined with cyclophosphamide
  (intravenous) if residual disease disease < 2 cm
Evaluation following
adjuvant treatment
Figure 4 Adjuvant treatment of stages IIB, IIC, III epithelial ovarian cancer
with residual disease after surgery 
EPITHELIAL  OVARIAN CANCER
STAGES IIB, C, III, IV
AT THE END OF ADJUVANT TREATMENT
Standard
there is no standard
Options
· stop treatment
· abdomino-pelvic irradiation
· intraperitoneal chemotherapy
· continue the same chemotherapy
· other chemotherapy
· intensification
Follow-up
Figure 5 Management of stages IIB, IIC, III, IV epithelial ovarian cancer at
the end/after adjuvant treatment Ovarian cancer 23
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The effect of changing to another chemotherapy protocol after
six cycles of chemotherapy has not been evaluated. 
When macroscopic residual disease is found at second-look
surgery, abdomino-pelvic radiotherapy is not recommended
(standard, level of evidence C). 
Alpha-interferon combined with intraperitoneal carboplatin
after platin-based chemotherapy and second look surgery does not
improve survival (level of evidence C). 
It is recommended that patients be included in therapeutic trials. 
HORMONE REPLACEMENT THERAPY 
There is no standard. Hormone replacement therapy (HRT) after
the menopause has not been shown to be associated with the
development of ovarian adenocarcinomas in epidemiological
studies (level of evidence B). There is no epidemiological, biolog-
ical or clinical data to preclude the use of HRT in patients previ-
ously treated for cancer of the ovary in the absence of other
contra-indications to HRT. There is no evidence that HRT is asso-
ciated with the recurrence of ovarian cancer after treatment. Breast
surveillance is recommended in these patients because of the
possible association of ovarian and breast cancers. There is no
consensus as to the combined use of progestogens and oestrogens
following hysterectomy. 
POST-TREATMENT ASSESSMENT 
Assessment at the end of chemotherapy includes clinical examina-
tion, measurement of tumour markers (in particular CA125) and a
CT scan of the abdomen and pelvis (level of evidence B) to iden-
tify any residual mass (standard). Abdominal ultrasound should be
used in addition to CT scanning to monitor parenchymal hepatic or
splenic metastases (level of evidence B) (option). 
If there is doubt as to the persistence of disease in the region of
the right hemi-diaphragm, MRI should be used (level of evidence B)
(option). A normal CA125 level after six courses of chemotherapy
does not confirm a histological complete response, whereas an
elevated serum level at this time confirms the absence of a
complete response. Because of the variability in results with
different methods, each patient should be followed using the same
test method, preferably carried out at the same laboratory. 
FOLLOW-UP 
The follow-up of patients without clinical signs is based on clin-
ical examination (standard). In the absence of curative treatment
for relapsed disease, there is no consensus as to the necessity 
and frequency of CA125 assays (option) during follow-up.
Surveillance by CT and ultrasonography are only indicated if
tumour markers have not been reliable. Surveillance by MRI is not
recommended (level of evidence B). There are no data to define
the frequency of surveillance. 
If there is an increase in a previously normal CA125 level, the
assay should be repeated after 2–3 weeks to confirm the increase
and to calculate the time of doubling or the rate of progression. If a
relapse is suspected in the presence of clinical signs and/or a
confirmed elevation of tumour markers, the first investigation to
undertake is a CT scan of the abdomen and pelvis. An abdomino-
pelvic ultrasound need only be done if the CT is negative.
Immuno-scintigraphy is only indicated if both the CT and ultra-
sound are negative (level of evidence B). 
Exceptions might apply for patients in clinical trials. 
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